Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
about
Higher serum levels of rheumatoid factor and anti-nuclear antibodies in helicobacter pylori-infected peptic ulcer patientsApoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists.Targeted delivery systems for biological therapies of inflammatory diseases.Synovial cell production of IL-26 induces bone mineralization in spondyloarthritis.
P2860
Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Golimumab: a new anti-TNF-alph ...... is and ankylosing spondylitis.
@en
Golimumab: a new anti-TNF-alph ...... is and ankylosing spondylitis.
@nl
type
label
Golimumab: a new anti-TNF-alph ...... is and ankylosing spondylitis.
@en
Golimumab: a new anti-TNF-alph ...... is and ankylosing spondylitis.
@nl
prefLabel
Golimumab: a new anti-TNF-alph ...... is and ankylosing spondylitis.
@en
Golimumab: a new anti-TNF-alph ...... is and ankylosing spondylitis.
@nl
P2860
P356
P1476
Golimumab: a new anti-TNF-alph ...... is and ankylosing spondylitis.
@en
P2093
Paraskevi V Voulgari
P2860
P304
P356
10.1586/ECI.10.49
P577
2010-09-01T00:00:00Z